We are pleased to announce that two exciting projects, brought to Keyholder by Longacre Funding Partners, have been approved by the Keyholder investment committee for final due-diligence and verification. These are Vaxeal and Celex.
Celex converts cancer from a killer disease, to a chronic disease, by preventing cancer from metastasising and being invasive. This is achieved by blocking the electrical signals from cancer cell to cancer cell that are necessary for the formation and growth of a tumour. The drugs which have been patent protected, and are effective, are already on the market for angina and have no unacceptable side effects. Celex owns the patents as a repurposed drug and testing is required in a clinical phase 2 trial.
Investment in Celex is expected to commence and be available to investors in July 2018.